Psora-4
Based on 1 Customer Validation
Psora-4 (5-(4-Phenylbutoxy) psoralen) is a selective Kv1.3 blocker (Kd = 3 nM). Psora-4 increases mitochondrial ROS production, activates stress response genes including daf-16 targets and heat shock proteins, reduces triglyceride accumulation, extends lifespan and healthspan in C. elegans, and increases resistance to Paraquat-induced oxidative stress. Psora-4 can be used for research on psoriasis and obesity.
For research use only. We do not sell to patients.
- Purity : 99.7%
- CAS No.: 724709-68-6
- Formula: C21H18O4
- Molecular Weight:334.37
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[3]|
Kv1.3 3 nM (Kd) |
In Vitro
Inhibition of Kv1.3 by Psora-4 (1 µM; 0-36 h) does not alter the proliferation of 3T3-L1 preadipocytes, indicating that the role of Kv1.3 in cell cycle progression is independent of plasma membrane channel flux[3].
Psora-4 (100 μM; 2 days) increases mitochondrial ROS production in wild-type N2 C. elegans after 2 days of treatment[4].
Psora-4 (100 μM) extends the healthspan of wild-type N2 Caenorhabditis elegans, and treated animals spend a greater proportion of their lifespan in optimal health[4].
Psora-4 (100 μM) fails to further extend the lifespan of wild-type N2 C. elegans under caloric restriction conditions, indicating that it acts as a caloric restriction mimetic[4].
Psora-4 (100 μM; 2 days) reduces total triglyceride accumulation, particularly TAG containing long-chain fatty acyl groups, in wild-type N2 C. elegans[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:3T3-L1 preadipocytes
-
Concentration:1 µM
-
Incubation Time:0, 12, 24, and 36 h
-
Result:Caused no changes in proliferation compared to untreated cells.
Chemical Information
-
CAS No. 724709-68-6
-
Appearance Solid
-
Molecular Weight 334.37
-
Formula C21H18O4
-
Color White to off-white
-
SMILES
O=C1C=CC2=C(OCCCCC3=CC=CC=C3)C4=C(OC=C4)C=C2O1
-
Synonyms
5-(4-Phenylbutoxy)psoralen
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (299.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9907 mL | 14.9535 mL | 29.9070 mL | 74.7675 mL |
| 5 mM | 0.5981 mL | 2.9907 mL | 5.9814 mL | 14.9535 mL | |
| 10 mM | 0.2991 mL | 1.4953 mL | 2.9907 mL | 7.4767 mL | |
| 15 mM | 0.1994 mL | 0.9969 mL | 1.9938 mL | 4.9845 mL | |
| 20 mM | 0.1495 mL | 0.7477 mL | 1.4953 mL | 3.7384 mL | |
| 25 mM | 0.1196 mL | 0.5981 mL | 1.1963 mL | 2.9907 mL | |
| 30 mM | 0.0997 mL | 0.4984 mL | 0.9969 mL | 2.4922 mL | |
| 40 mM | 0.0748 mL | 0.3738 mL | 0.7477 mL | 1.8692 mL | |
| 50 mM | 0.0598 mL | 0.2991 mL | 0.5981 mL | 1.4953 mL | |
| 60 mM | 0.0498 mL | 0.2492 mL | 0.4984 mL | 1.2461 mL | |
| 80 mM | 0.0374 mL | 0.1869 mL | 0.3738 mL | 0.9346 mL | |
| 100 mM | 0.0299 mL | 0.1495 mL | 0.2991 mL | 0.7477 mL |